This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXNPEH6028C_L.jpg
The company, one of the largest U.S. pharmacies, had been relying on gains from administering COVID-19 vaccines to tide over losses from low prescription volumes and a weak flu season that has hampered over-the-counter sales of health and wellness products in recent quarters.
However, prescription volumes improved in the third quarter amid a drop in COVID-19 cases in the United States and easing of social-distancing protocols and lockdowns.
Walgreens said it had administered more than 25 million COVID-19 vaccinations to date out of the 326.5 million shots given in the United States as of June 30.
Same-store sales at its U.S. pharmacies rose 6.4% in the third quarter as it filled 312.1 million prescriptions.
Walgreens raised its 2021 adjusted earnings per share forecast from mid-to-high single digit growth to around 10 percent growth.
Net income attributable to the company was $1.2 billion, or $1.38 per share, for the quarter ended May 31, compared with a net loss of $1.71 billion, or $1.95 per share, a year earlier.
